Stéphane Bancel, Moderna CEO (AP Photo/Markus Schreiber)

Up­dat­ed: Mod­er­na: Not enough flu cas­es in PhI­II tri­al yet to tell ef­fi­ca­cy

One of Mod­er­na’s Phase III stud­ies for its in­fluen­za vac­cine can­di­date for adults, dubbed mR­NA-1010, did not have enough cas­es at the time of the in­ter­im ef­fi­ca­cy analy­sis to de­clare ear­ly suc­cess, the com­pa­ny an­nounced Tues­day.

A rep­re­sen­ta­tive for Mod­er­na told End­points News there were not enough peo­ple in­fect­ed dur­ing the time of the study.

The NIH’s Da­ta and Safe­ty Mon­i­tor­ing Board rec­om­mend­ed con­tin­u­ing to test the shot for ef­fi­ca­cy in the North­ern Hemi­sphere tri­al, which is sup­posed to pro­tect against four dif­fer­ent in­fluen­za strains.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.